APLISOL is one of two purified-protein derivative (PPD) tuberculin antigens that are licensed by the United States Food and Drug Administration (FDA) for use in performing tuberculin skin tests. The manufacturer notified CDC that they anticipate a supply interruption of APLISOL 5 mL (50 tests) beginning in June 2019, followed by a supply interruption of APLISOL 1 mL (10 tests) in November 2019.
The expected shortage of APLISOL 1 mL (10 tests) could occur before November 2019, if demand increases before then. The 3-10 month timeframe for the nationwide shortage is the manufacturer's current estimate and is subject to change.
We have confirmed with our major clinic locations that this has not and will not affect daily operations; however, they have ensured us that they are also working on additional options (Tubersol) in the event the backorder does occur.
Please visit the following link for additional information with regards to the shortage. Click Here.
Posted: August 1, 2019